ABOUT PROGENERON

Progeneron is a first-of-its-kind multi-action product created to mitigate the progression and symptoms associated with Palmar Fibromatosis (Dupuytren's contracture). It has been the subject of a 90-day IRB safety study and a 180-day IRB efficacy study in which 95% of the population showed no signs of disease progression. Progeneron is owned and operated by Eresina, LLC (EresinaLabs.com), a biotech research and development company specializing in fibrotic tissue disorders and diseases. Clinical data, including studies, is available to physicians via our Progeneron Physician Portal and to the public, where applicable, via the Scharp Lacy Research Institute, a 501(c)(3) nonprofit institution focusing on Diabetes, Stem Cell, and Dupuytren's research.